KRT5 Antibody

What is KRT5 and what tissues normally express this protein?

KRT5 (Keratin 5) is a 58 kDa type II cytokeratin protein that forms intermediate filaments in epithelial cells. It is specifically expressed in the basal layer of the epidermis together with its binding partner KRT14 . This type II cytokeratin belongs to the keratin gene family and forms heterotypic keratin chain pairs that are coexpressed throughout the differentiation of simple and stratified epithelial tissues .

The protein is normally expressed in:

• Basal cells of squamous and glandular epithelia

• Myoepithelial cells

• Mesothelium

• Basal cells of the prostate

• Myoepithelial cells of the breast

• Glandular epithelia

Understanding KRT5's normal expression pattern is essential for proper interpretation of immunohistochemical results, especially when used as a diagnostic marker.

What is the molecular structure and characteristics of KRT5?

KRT5 is classified as a type II (basic or neutral) keratin that belongs to the intermediate filament family. Its genomic location is on chromosome 12q12-q13, within a cluster of type II cytokeratin genes . The protein has the following key characteristics:

• Molecular weight: 58 kDa

• Uniprot ID: P13647

• Entrez Gene ID: 3852

• Localization: Cytoplasmic

The complete amino acid sequence is proprietary for commercial antibodies, but the recombinant fragment used as immunogen for some antibodies covers approximately amino acids 316-590 of the human KRT5 protein . The epitope sequence for some antibodies, such as CPTC-KRT5-1, is "AQYEEIANR" .

The protein's structure enables it to form heterodimers with KRT14, which is critical for maintaining epithelial cell integrity and mechanical resilience.

What types of KRT5 antibodies are available for research applications?

Researchers can choose from several types of KRT5 antibodies, each with distinct characteristics:

When selecting an antibody, researchers should consider the specific application, species reactivity (most KRT5 antibodies are human-specific), and the epitope recognized . For reproducible results, recombinant monoclonal antibodies offer advantages in terms of consistency and defined epitope recognition.

How do I validate a KRT5 antibody before use in my experimental system?

Proper validation of KRT5 antibodies is critical for ensuring reliable experimental results. A methodical approach includes:

• Positive control tissues: Use human tonsil, esophagus, or bladder tissue as positive controls for immunohistochemistry, as these tissues reliably express KRT5 .

• Specificity testing: Verify the antibody detects a protein band of approximately 58 kDa in Western blot analyses.

• Cross-reactivity assessment: Ensure the antibody does not cross-react with other keratin family members, particularly those with similar molecular weights.

• Comparison with literature: Compare staining patterns with published results to confirm expected tissue distribution.

• Antibody titration: Determine the optimal antibody concentration by testing a range of dilutions. For rabbit antibodies, start with 0.2-0.5 μg/ml for IHC/IF/ICC and 20-50 ng/ml for Western blot; for mouse antibodies, start with 2-5 μg/ml for IHC/IF/ICC and 0.2-0.5 μg/ml for Western blot .

This systematic validation ensures reliable, reproducible results across experiments.

What are the optimal protocols for using KRT5 antibodies in immunohistochemistry?

For optimal immunohistochemical detection of KRT5 in formalin-fixed, paraffin-embedded tissues, follow this methodological approach:

• Antigen retrieval: Heat-induced epitope retrieval (HIER) is essential. Use 10mM Tris with 1mM EDTA, pH 9.0, and heat at 95°C for 45 minutes, followed by cooling at room temperature for 20 minutes .

• Primary antibody incubation: Apply KRT5 antibody at 1-2 μg/ml concentration and incubate for 30 minutes at room temperature .

• Detection system: Use an HRP-polymer system with 30-minute incubation.

• Chromogen development: Apply DAB (3,3'-diaminobenzidine) for 5 minutes.

• Counterstaining: Use hematoxylin for nuclear visualization.

The cytoplasmic staining pattern should be evaluated, with positive cells showing distinct cytoplasmic filamentous staining. This protocol has been validated using human tonsil tissue, which serves as an excellent positive control due to its consistent KRT5 expression in basal epithelial cells .

How should KRT5 antibodies be stored and handled to maintain reactivity?

Proper storage and handling of KRT5 antibodies is crucial for maintaining their reactivity and extending shelf life:

For lyophilized formats, reconstitute according to manufacturer instructions using sterile techniques. Most KRT5 antibodies are formulated in PBS with preservatives such as sodium azide (0.02-0.05%) and may contain stabilizers like BSA (0.05%) .

The stability at 4°C is typically one month, while properly stored frozen antibodies generally maintain reactivity for up to 12 months . Always centrifuge briefly before use to collect all liquid at the bottom of the vial.

How can KRT5 antibodies be used for differential diagnosis in cancer pathology?

KRT5 antibodies serve as powerful diagnostic tools for distinguishing between different cancer types, with particular utility in the following clinical scenarios:

• Mesothelioma vs. Metastatic Carcinoma: KRT5 antibodies are valuable in differentiating epithelioid mesothelioma from metastatic carcinoma in pleural tissue, providing crucial diagnostic information when histological assessment alone is challenging .

• Squamous Cell Carcinoma Identification: Almost all squamous cell carcinomas express KRT5, making this antibody highly sensitive for identifying squamous differentiation. When used in combination with p63, KRT5 antibodies provide both high sensitivity and specificity for confirming squamous cell origin .

• Transitional Cell Carcinoma Assessment: Approximately half of transitional cell carcinomas express KRT5, making it a useful component of a diagnostic panel for these tumors .

• Poorly Differentiated Tumors: KRT5 is expressed in many undifferentiated large cell carcinomas, helping pathologists determine the tissue of origin in challenging cases .

• Breast Pathology: KRT5 staining helps identify myoepithelial cells in breast tissue, which is valuable for distinguishing in situ from invasive breast carcinomas, as the myoepithelial layer is preserved in in situ lesions but lost in invasive disease .

The methodological approach should include appropriate controls and careful interpretation of staining patterns in the context of a comprehensive immunohistochemical panel.

What are the troubleshooting strategies for weak or inconsistent KRT5 immunostaining?

When encountering weak or inconsistent KRT5 immunostaining, implement these systematic troubleshooting approaches:

• Optimize antigen retrieval:

  • Extend heating time to 45-60 minutes

  • Ensure buffer pH is 9.0 (alkaline) as this is optimal for KRT5 epitope exposure

  • Try alternative retrieval methods if Tris-EDTA is ineffective

• Antibody titration and incubation:

  • Test multiple antibody concentrations (0.5-5 μg/ml range)

  • Extend primary antibody incubation to overnight at 4°C

  • Consider using a more sensitive detection system

• Tissue fixation assessment:

  • Overfixation can mask epitopes; use tissues fixed for 24-48 hours

  • Underfixation may cause tissue degradation; ensure minimum 6-12 hours fixation

  • Try different tissue blocks if available

• Detection system enhancement:

  • Use amplification systems (e.g., tyramide signal amplification)

  • Switch to a more sensitive polymer-based detection system

  • Extend chromogen development time (monitor to prevent background)

• Antibody quality control:

  • Test a new antibody lot or alternative clone

  • Include reliable positive control tissue (tonsil or esophagus) in each run

  • Ensure antibody has not undergone multiple freeze-thaw cycles

Systematically document each modification to identify which variables most significantly affect staining quality for your specific tissue samples.

How can KRT5 antibodies be integrated into multiplex immunohistochemistry panels?

Multiplex immunohistochemistry (mIHC) with KRT5 antibodies requires careful optimization for simultaneous detection with other markers:

• Panel design considerations:

  • Pair KRT5 (cytoplasmic marker) with nuclear markers like p63 for squamous differentiation

  • Combine with other keratin markers (KRT14, KRT7, KRT20) for comprehensive epithelial typing

  • Include cell-type specific markers relevant to your research question

• Sequential staining protocol:

  • Begin with heat-sensitive epitopes first

  • Use KRT5 antibody at 0.5-1 μg/ml (lower than single-plex concentration)

  • Perform complete signal development before epitope stripping

  • Use spectral unmixing software for fluorescent multiplex applications

• Antibody selection for multiplex compatibility:

  • Choose antibodies from different host species to avoid cross-reactivity

  • Select clones validated for multiplexing applications

  • Consider recombinant rabbit monoclonal antibodies for highest specificity

• Signal separation strategies:

  • For chromogenic mIHC: Use distinctly colored chromogens (DAB for KRT5)

  • For fluorescent mIHC: Select fluorophores with minimal spectral overlap

  • Employ tyramide signal amplification for sequential detection with same-species antibodies

This methodological approach allows researchers to obtain complex information about tissue architecture and cellular relationships while preserving spatial context .

What are the quantitative approaches for analyzing KRT5 expression in tissue samples?

Quantitative analysis of KRT5 expression requires standardized approaches to generate reproducible and comparable data:

• Digital image analysis workflow:

  • Capture high-resolution whole slide images with consistent exposure settings

  • Apply tissue segmentation to identify regions of interest

  • Use cell segmentation algorithms to identify individual cells

  • Implement intensity thresholding calibrated with positive controls

  • Calculate H-score (combining intensity and percentage of positive cells) or other quantitative metrics

• Expression scoring methods:

  Score	Staining Intensity	Percentage Positive
  0	Negative	<5%
  1+	Weak	5-25%
  2+	Moderate	26-50%
  3+	Strong	>50%

  • H-score calculation: ∑(i × Pi) where i = intensity (0-3) and Pi = percentage of cells

• Quality control measures:

  • Include standard positive controls in each batch

  • Normalize intensity measurements to internal controls

  • Perform replicate analyses to establish measurement variance

  • Validate quantification with manual scoring by pathologists

• Data interpretation guidelines:

  • Establish tissue-specific thresholds for positivity

  • Consider heterogeneity of expression within samples

  • Correlate expression levels with clinical variables for research applications